In string of deals, Lilly nabs ultra rare eye disease gene therapy and RNAi partnernews2025-11-10T16:00:46+00:00November 10th, 2025|Endpoints News|
#AHA25: CRISPR Therapeutics’ gene editing therapy halves cholesterol and triglycerides in early trialnews2025-11-10T15:25:01+00:00November 10th, 2025|Endpoints News|
Catalent lays off more gene therapy workers in Baltimorenews2025-11-10T14:13:30+00:00November 10th, 2025|Endpoints News|
Ex-Lilly Diabetes leaders hunt for new obesity drugs at VC firmnews2025-11-10T14:00:26+00:00November 10th, 2025|Endpoints News|
Roche reports two Phase 3 wins for its BTK inhibitor in multiple sclerosisnews2025-11-10T12:30:39+00:00November 10th, 2025|Endpoints News|
#AHA25: Ionis claims curative potential for Tryngolza in severe triglyceride diseasenews2025-11-10T12:03:22+00:00November 10th, 2025|Endpoints News|
AI biotech Iambic raises $100M from ARK, Regeneronnews2025-11-10T12:00:53+00:00November 10th, 2025|Endpoints News|
#AASLD25: Vir presents new hepatitis D data and ramps up bullish Phase 3 plansnews2025-11-09T23:15:42+00:00November 9th, 2025|Endpoints News|
#AHA25: Merck reports pivotal PCSK9 pill data in race to beat AstraZeneca to marketnews2025-11-09T22:00:40+00:00November 9th, 2025|Endpoints News|
#AHA25: Amgen’s cholesterol drug cuts first-time cardiovascular events by a quarternews2025-11-08T15:10:59+00:00November 8th, 2025|Endpoints News|
